GSK has developed a new propellant ... 35 million people with asthma around the world. Inhalers are also a major contributor to the carbon footprint of healthcare systems, according to the company.

40% of the drugmaker’s carbon footprint is shackled to its supply chain, and suppliers make up a “substantial part” of GSK’s global effect on water, waste and biodiversity, the company ...

The former facility will manufacture products based on Multiple Antigen Presenting System (MAPS ... which GSK said there is an “ever-increasing demand”. As for the site’s carbon footprint ...

The biotech, which paid Astellas $65 million to regain rights to AFX3772 in February, also argues its multiple antigen-presenting system, MAPS ... GSK’s existing scientific footprint in the ...

with more than 40% of its carbon footprint coming from the procurement of those materials. “We established that 65% of our suppliers did not have an active programme in place to reduce energy costs,” ...

GSK expanded its footprint at 200 CambridgePark Drive in 2023, reaching almost 200,000 square feet on their lease under real estate management firm King Street Properties. Prior to 2023 ...

GSK is continuing to grow its footprint in the biotech hub of Boston ... As part of the deal, GSK received the exclusive global license to Wave’s preclinical RNA editing program to treat ...

About GSK Consumer Healthcare GSK Consumer Healthcare combines science and consumer insights to create innovative world-class health care brands that consumers trust and experts recommend for oral ...

Called GSK Asia House, the facility in Rochester Park functions as the commercial hub for more than half of the company's global healthcare operations. More than 800 employees work there, including ...